154 related articles for article (PubMed ID: 16101439)
21. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
Morse MA
Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory properties of double-helix-forming circular oligonucleotides.
Azhayeva E; Azhayev A; Auriola S; Tengvall U; Urtti A; Lönnberg
Nucleic Acids Res; 1997 Dec; 25(24):4954-61. PubMed ID: 9396802
[TBL] [Abstract][Full Text] [Related]
23. High Boron-loaded DNA-Oligomers as Potential Boron Neutron Capture Therapy and Antisense Oligonucleotide Dual-Action Anticancer Agents.
Kaniowski D; Ebenryter-Olbińska K; Sobczak M; Wojtczak B; Janczak S; Leśnikowski ZJ; Nawrot B
Molecules; 2017 Aug; 22(9):. PubMed ID: 28832537
[TBL] [Abstract][Full Text] [Related]
24. [Antisense oligonucleotides with antitumor activity].
Otvös L; Sági G
Magy Onkol; 2004; 48(3):221-7. PubMed ID: 15520872
[TBL] [Abstract][Full Text] [Related]
25. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
26. Antisense oligonucleotide derivatives as gene-targeted drugs.
Knorre DG; Vlassov VV
Biomed Sci; 1990 Apr; 1(4):334-43. PubMed ID: 1723003
[TBL] [Abstract][Full Text] [Related]
27. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development.
Orum H; Wengel J
Curr Opin Mol Ther; 2001 Jun; 3(3):239-43. PubMed ID: 11497347
[TBL] [Abstract][Full Text] [Related]
28. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?
Rayburn ER; Zhang R
Drug Discov Today; 2008 Jun; 13(11-12):513-21. PubMed ID: 18549978
[TBL] [Abstract][Full Text] [Related]
29. A status update of modified oligonucleotides for chemotherapeutics applications.
Sanghvi YS
Curr Protoc Nucleic Acid Chem; 2011 Sep; Chapter 4():Unit 4.1.1-22. PubMed ID: 21901670
[TBL] [Abstract][Full Text] [Related]
30. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.
Ciardiello F; Caputo R; Troiani T; Borriello G; Kandimalla ER; Agrawal S; Mendelsohn J; Bianco AR; Tortora G
Int J Cancer; 2001 Jul; 93(2):172-8. PubMed ID: 11410862
[TBL] [Abstract][Full Text] [Related]
31. Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment.
Spänkuch B; Strebhardt K
Curr Pharm Des; 2008; 14(11):1098-112. PubMed ID: 18473857
[TBL] [Abstract][Full Text] [Related]
32. Antisense oligonucleotide drug design.
Schiavone N; Donnini M; Nicolin A; Capaccioli S
Curr Pharm Des; 2004; 10(7):769-84. PubMed ID: 15032702
[TBL] [Abstract][Full Text] [Related]
33. Oligonucleotides as inhibitors of human immunodeficiency virus.
Field AK
Curr Opin Mol Ther; 1999 Jun; 1(3):323-31. PubMed ID: 11713797
[TBL] [Abstract][Full Text] [Related]
34. LNA-antisense rivals siRNA for gene silencing.
Jepsen JS; Wengel J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
[TBL] [Abstract][Full Text] [Related]
35. Efficiency of antisense oligonucleotide drug discovery.
Bennett CF
Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):215-24. PubMed ID: 12162703
[TBL] [Abstract][Full Text] [Related]
36. Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression.
Mercatante DR; Kole R
Biochim Biophys Acta; 2002 Jul; 1587(2-3):126-32. PubMed ID: 12084454
[TBL] [Abstract][Full Text] [Related]
37. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
38. Preclinical and clinical experience of antisense therapy for solid tumors.
Webb MS; Zon G
Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
[TBL] [Abstract][Full Text] [Related]
39. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.
Warzocha K; Wotowiec D
Leuk Lymphoma; 1997 Jan; 24(3-4):267-81. PubMed ID: 9156656
[TBL] [Abstract][Full Text] [Related]
40. Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development.
Holmlund JT
Ann N Y Acad Sci; 2003 Dec; 1002():244-51. PubMed ID: 14751839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
